Histological subtype is the most important determinant of survival in metastatic papillary thyroid cancer
| العنوان: | Histological subtype is the most important determinant of survival in metastatic papillary thyroid cancer |
|---|---|
| المؤلفون: | Frideriki Patakiouta, Eleni Doumala, Kalliopi Pazaitou-Panayiotou, Maria Boudina, Pashalia K Iliadou, Athanasios Tzemailas, Alexandra Chrisoulidou |
| المصدر: | Thyroid Research, Vol 4, Iss 1, p 12 (2011) Thyroid Research |
| بيانات النشر: | Springer Science and Business Media LLC, 2011. |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Pathology, lcsh:RC648-665, endocrine system diseases, Endocrine and Autonomic Systems, business.industry, Research, Endocrinology, Diabetes and Metabolism, Improved survival, Radioiodine therapy, Disease, medicine.disease, lcsh:Diseases of the endocrine glands. Clinical endocrinology, Papillary thyroid cancer, Endocrinology, Treatment modality, Internal medicine, Follicular phase, papillary thyroid carcinoma, distant metastases, medicine, Risk of death, business, Thyroid cancer |
| الوصف: | Background Papillary thyroid cancer (PTC) comprises the commonest type of thyroid cancer and carries the highest rate of survival. However, when metastatic disease occurs, survival is significantly affected. Methods We aimed to identify prognostic histopathological and clinical factors that modify survival in metastatic PTC. All cases of metastatic PTC treated at our department in the last 20 years were reviewed and analyzed. Results Histological subtype was the most important determinant of survival, as classic PTC demonstrated clearly improved survival compared to follicular subtype of PTC and other less frequently seen histological subtypes. The instant risk of death for the other histological subtypes was 4.56 times higher than the risk for the classic papillary type. Overall, a 10-year survival of 76.6% in our patients was seen. Conclusions Patients with aggressive variants of PTC are more at risk for the development of metastatic disease. In these patients, established treatment modalities (surgery, radioiodine therapy) should be offered promptly, as well as close follow-up. |
| تدمد: | 1756-6614 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59952a78c1ad9279f93de86345301780 https://doi.org/10.1186/1756-6614-4-12 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....59952a78c1ad9279f93de86345301780 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 17566614 |
|---|